The University of Southampton
University of Southampton Institutional Repository

Letter. Targeting C-reactive protein for the treatment of cardiovascular disease

Pepys, M.B., Hirschfield, G.M., Tennent, G.A., Gallimore, J.R., Kahan, M.C., Bellotti, V., Hawkins, P.N., Myers, R.M., Smith, M.D., Polara, A., Cobb, A.J.A., Vey, S.V., Aquilina, J.A., Robinson, C.V., Sharif, I., Gray, G.A., Sabin, C.A., Jenvey, M.C., Kolstoe, S.E., Thompson, D. and Wood, S.P. (2006) Letter. Targeting C-reactive protein for the treatment of cardiovascular disease Nature, 440, (7088), pp. 1217-1221. (doi:10.1038/nature04672).

Record type: Article


Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement(1), increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively(2,3). Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement(4). Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP2,3. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.

PDF RMMnature.pdf_[yotpla].pdf - Version of Record
Restricted to Registered users only
Download (873kB)

More information

Published date: April 2006


Local EPrints ID: 37645
ISSN: 0028-0836
PURE UUID: c1124ace-cbcf-415c-8f3b-c9974a94679e

Catalogue record

Date deposited: 25 May 2006
Last modified: 17 Jul 2017 15:41

Export record



Author: M.B. Pepys
Author: G.M. Hirschfield
Author: G.A. Tennent
Author: J.R. Gallimore
Author: M.C. Kahan
Author: V. Bellotti
Author: P.N. Hawkins
Author: R.M. Myers
Author: M.D. Smith
Author: A. Polara
Author: A.J.A. Cobb
Author: S.V. Vey
Author: J.A. Aquilina
Author: C.V. Robinson
Author: I. Sharif
Author: G.A. Gray
Author: C.A. Sabin
Author: M.C. Jenvey
Author: S.E. Kolstoe
Author: D. Thompson
Author: S.P. Wood

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.